CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

More documents

Recommendations

Info

156. Cross, A.J., Peters, U., Kirsh, V.A., Andriole, G.L., Reding, D., Hayes, R.B., and Sinha, R.: A Prospective Study of Meat and Meat-Mutagens and Prostate Cancer Risk. Cancer Res. 2005 Dec 15;65(24):11779-84. 157. Kirsh, V.A., Hayes, R.B., Mayne, S.R., Subar, A., Dixon, L.B., Albanes, D., Andriole, G.L., Urban, D. and Peters, U.: Supplemental and dietary vitamin E, β-carotene and vitamin C, and risk of prostate cancer JNCI 98(4):245-254, 2006. 158. Grubb, R.L., III, Andriole, G.L.: Can Preoperative PSA Doubling Time and PSA Velocity Predict Outcomes Following Radical Prostatectomy? Nat Clin Pract Urol 3(6):306-307, 2006. 159. Bullock, T.L., and Andriole, G.L.: Emerging drug therapies for benign prostatic hyperplasia. Expert Opin. Emerging Drugs. 11(1):111-123, 2006. 160. Crawford, E.D., Pinsky, P.F., Chia, D., Kramer, B.S., Hayes, R., Fagerstrom, R, Andriole, G.L., Reding, D., Gelmann, E.P., Levin, D., and Gohagen, J.K.: Prostate Specific Antigen Changes as Related to the Initial Prostate Specific Antigen: Data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. J Urol 175:1286-1290, 2006. 161. Andriole, G.L., Marberger, M. And Roehrborn, C.G.: Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5α-reductase inhibitor dutasteride. J Urol 175:1657-1662, 2006. 162. Koralek, D.O., Peters, U., Andriole, G.L., Reding, D., Kirsh, V., Subar, A., Schatzkin, A., Hayes, R., and Leitzmann, M.F.: A Prospective Study of Dietary Alpha-Linolenic Acid and the Risk of Prostate Cancer (United States). Cancer Causes Control 7:783-791, 2006. 163. Venkatesh, R., Weld, K., Ames, C.D., Figenshau, R.S., Sundaram, C.P., Andriole, G.L., Clayman, R.V. and Landman, J.: Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology 67(6):1169-1174, 2006. 164. Andriole, G.L., Bostwick, D., Civantos, F., Epstein, J., Lucia, M.S., McConnell, J. and Roehrborn, C.G.: Re: The Effects of 5α-Reductase Inhibitors on the Natural History, Detection and Grading of Prostate Cancer: Current State of Knowledge. Letter to the Editor, J Urol 176(1):408-409, 2006. 165. Pinsky, P.F., Kramer, B.S., Crawford, E.D., Grubb, R.L., Urban, D.A., Andriole, G.L., Chia, D., Levin, D.L., Gohagan, J.K.: Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 68(2)352-256, 2006. 166. Koralek, D.O., Peters U., Andriole, G.L., Reding, D., Kirsh, V., Subar, A., Schatzkin, A., Hayes, R., Leitzmann, M.F.: A Prospective Study of Dietary Alpha-Linolenic Acid and the Risk of Prostate Cancer (United States). Cancer Causes Control 17(6):783-791, 2006/ 167. Andriole, G.L., Djavan, B., Fleshner, N., and Schroder, F.: The Case for Prostate Cancer Screening with Prostate-Specific Antigen. European Urology Supplements 5:737-745, 2006. 168. Andriole, G.L.: 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond. European Urology Supplements 5:746-751, 2006 169. Marks, L.S., Andriole, G.L., Fitzpatrick, J.M., Schulman, C. and Roehrborn, C.G.: The interpretation of serum prostate specific antigen levels in men receiving 5-alpha reductase inhibitors: A review and clinical recommendations. J Urol 176(3):868-874, 2006. 32
170. Marks, L.S., Roehrborn, C.G. and Andriole, G.L.: Prevention of BPH disease in men with enlarged prostate. J Urol 176(4):1299-1306, 2006. 171. Skolarus, T.A. and Andriole, G.L.: Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer. Men’s Urologic Health 1(3):1-8, 2006. 172. Venkatesh, R., Sundaram, C.P., Figenshau R.S., Yan, Y., Andriole, G.L., Clayman, R.V. and Landman, J.: Prospective Randomized Comparison of Cutting and Dilating Disposable Trocars for Access During Laparoscopic Renal Surgery. JSLS 11:198-203, 2007. 173. Andriole, G.L.: Words of Wisdom. RE: Extended 21-Sample Needle Biopsy Protocol for diagnosis of Prostate Cancer in 1000 Consecutive Patients. Eur Urology 52:430-5, 2007. 174. Peters, U., Foster, C.B., Chatterjee, N., Schatzkin, A., Reding, D., Andriole, G.L., Crawford, E.D., Sturup, S., Chanock, S.J. and Hayes, R.B.: Serum selenium and risk of prostate cancer- a nested casecontrol study. Am J Clin Nutr 85(1):209-217, 2007. 175. Pinsky, P.F., Crawford, E.D., Kramer B.S., Andriole, G.L., Gelmann, E.P., Grubb, R.L., Greenlee, R., and Gohagan, J.K.: Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BJU Int 99(4):775-779, 2007. 176. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello, M.J., Fearnhead, P., Yu, K., Chatterjee, N., Wang, Z., Welch, R., Staats, B.J., Calle, E.E., Feigelson, H.S., Thun, M.J., Rodriguez, C., Albanes, D., Virtamo, J., Weinstein, S., Schumacher, F.R., Giovannucci, E., Willett, W.C., Cancel-Tassin, G., Cussenot, O., Valeri, A., Andriole, G.L., Gelmann, E.P., Tucker, M., Gerhard, D.S., Fraumeni, J.F. Jr., Hoover, R., Hunter, D.J., Chanock, S.J., and Thomas, G.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39(5):645-649, 2007. 177. Daugherty, S.E., Hayes, R.B., Yeager, M., Andriole, G.L., Chatterjee, N., Huang, W.Y., Isaacs, W.B. and Platz, E.A.: RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Cancer Epidemiology, Biomarkers & Prevention Prostate 67(8):849-854, 2007. 178. Schumacher, F.R., Feigelson, H.S., Cox, D.G., Haiman, C.A., Albanes, D., Buring, J., Calle, E.E., Chanock S.J., Colditz, G.A., Diver, W.R., Dunning, A.M., Freedman, M.L., Gaziano, J.M., Giovannucci, E., Hankinson, S.E., Hayes, R.B., Henderson, B.E., Hoover, R.N., Kaaks, R., Key, T., Kolonel, L.N., Kraft, P., LeMarchand, L., Ma, J., Pike, M.C., Riboli, E., Stampfer, M.J, Stram, D.O., Thomas, G., Thun, M.J., Travis, R., Virtamo, J., Andriole, G.L., Gelmann, E., Willett, W.C. and Hunter, D.J.: A Common 8q24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study. Cancer Res 67(7):2951-2956, 2007. 179. Pinsky, P.F., Andriole, G.L., Crawford, E. D., Chia, D., Kramer, B, Grubb, R.L., Greenlee, R. and Gohagan, J.K.: Prostate Specific Antigen Velocity and Prostate Cancer Gleason Grade and Stage. Cancer 109(8):1689-1695, 2007. 180. Anast, J.W., Andriole, G.L. and Grubb, R.L.: Managing the Local Complications of Locally Advanced Prostate Cancer. Curr Urol Rep 8(3):211-216, 2007. 181. Radwan, M.H., Yan, Y., Luly J.R., Figenshau, R.S., Brandes, S.B., Bhayani, S.B., Bullock, A.D., Liefu, Y, Andriole, G.L. and Kibel, A.S.: Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 69(6):1121-1127, 2007. 33
Page 1 and 2: CURRICULUM VITAE Gerald Louis Andri
Page 3 and 4: Chairman, Steering Committee, REDUC
Page 5 and 6: Period: 2002-2009 Grant Title: Comp
Page 7 and 8: Grant Title: A Double-Blind, Random
Page 9 and 10: implant) in Community-Based Patient
Page 11 and 12: BIBLIOGRAPHY: I. ABSTRACTS 1. Andri
Page 13 and 14: 27. Andriole, G.L., Coplen, D.E., a
Page 15 and 16: 52. Andriole, G.L., Rao, G.S., Kawa
Page 17 and 18: 76. Yan, Y., Andriole, G.L., Diaz,
Page 19 and 20: 99. Albala, D.M., Andriole, G.L., D
Page 21 and 22: 123. Grubb RL III, Black A, Church
Page 23 and 24: 28. Clayman, R.V., McClennan, B.W.,
Page 25 and 26: 60. Keetch, D.W., Andriole, G.L., C
Page 27 and 28: 90. Monk, T.G., Goodnough, L.T., Br
Page 29 and 30: Thermotherapy (P-TUMT) for the Trea
Page 31: 144. Andriole, G.L., Bostwick, D.,
Page 35 and 36: D.S., Chanock, S.J., Thun, M.J. and
Page 37 and 38: 14. Andriole, G.L.: Tumor markers i

CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?